The Gastrointestinal Cancer Channel is supported with funding from Gilead Sciences (Silver) and Revolution Medicines (Silver).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ESMO 2024 | DESTINY-Gastric03: T-DXd, fluoropyrimidine and pembrolizumab in HER2+ GEJA
Yelena Janjigian, MD, Memorial Sloan Kettering Cancer Center, New York, NY, discusses Part 2 of the DESTINY-Gastric03 trial (NCT04379596), which evaluated trastuzumab deruxtecan (T-DXd) with capecitabine and pembrolizumab as first-line therapy for HER2+ esophageal, gastric, or gastroesophageal junction adenocarcinoma (GEJA). The combination demonstrated promising antitumor activity, but combination of full-dose T-DXd with capecitabine and pembrolizumab had higher grade adverse events. This interview took place at the European Society for Medical Oncology (ESMO) 2024 Congress in Barcelona, Spain.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
